Cargando…

Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control

BACKGROUND: Immune checkpoint inhibitors (CPIs) have revolutionized oncologic therapy but can lead to immune‐related adverse events (irAEs). Corticosteroids are first‐line treatment with escalation to biologic immunosuppression in refractory cases. CPI‐related gastroenterocolitis (GEC) affects 20%‐5...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hughes, Michael S., Zheng, Hui, Zubiri, Leyre, Molina, Gabriel E., Chen, Steven T., Mooradian, Meghan J., Allen, Ian M., Reynolds, Kerry L., Dougan, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718531/ https://www.ncbi.nlm.nih.gov/pubmed/31286682 http://dx.doi.org/10.1002/cam4.2397

Ejemplares similares

Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis
por: Durbin, Sienna M, et al.
Publicado: (2020)

Case Report: Fulminant Celiac Disease With Combination Immune Checkpoint Therapy
por: Falade, Ayo S., et al.
Publicado: (2022)

Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis
por: Mooradian, Meghan J, et al.
Publicado: (2020)

Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study
por: Tiu, Bruce C, et al.
Publicado: (2022)

Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade
por: Reynolds, Kerry, et al.
Publicado: (2018)

Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA
por: Kalinich, Mark, et al.
Publicado: (2021)

Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
por: Zubiri, Leyre, et al.
Publicado: (2021)

Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade
por: Buchbinder, Elizabeth I., et al.
Publicado: (2021)

Immune checkpoint inhibitor-associated celiac disease
por: Badran, Yousef R, et al.
Publicado: (2020)

Pericardial disease in patients treated with immune checkpoint inhibitors
por: Gong, Jingyi, et al.
Publicado: (2021)

Budesonide treatment for microscopic colitis from immune checkpoint inhibitors
por: Hughes, Michael S., et al.
Publicado: (2019)

The role of IFN-γ-signalling in response to immune checkpoint blockade therapy
por: Wong, Chun Wai, et al.
Publicado: (2023)

Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors
por: Drobni, Zsofia D, et al.
Publicado: (2021)

Activation of G protein-coupled estrogen receptor signaling inhibits melanoma and improves response to immune checkpoint blockade
por: Natale, Christopher A, et al.
Publicado: (2018)

T-cell response to checkpoint blockade immunotherapies: from fundamental mechanisms to treatment signatures
por: Elliot, Thomas A.E., et al.
Publicado: (2023)

Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract
por: Dougan, Michael
Publicado: (2017)

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
por: Dubin, Krista, et al.
Publicado: (2016)

The Role of Immune Checkpoint Blockade in Uveal Melanoma
por: Wessely, Anja, et al.
Publicado: (2020)

Checkpoint blockade‐based immunotherapy in the context of tumor microenvironment: Opportunities and challenges
por: Duan, Jingjing, et al.
Publicado: (2018)

Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade
por: Johannet, Paul, et al.
Publicado: (2022)

COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis
por: Holmstroem, Rikke Boedker, et al.
Publicado: (2022)

Predictive factors of neoadjuvant immune checkpoint blockade in melanoma
por: Sarver, Melissa, et al.
Publicado: (2021)

Temporal Trends in Inpatient Oncology Census Before and During the COVID‐19 Pandemic and Rates of Nosocomial COVID‐19 Among Patients with Cancer at a Large Academic Center
por: Zubiri, Leyre, et al.
Publicado: (2021)

Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer
por: Wang, Shang-Jui, et al.
Publicado: (2020)

B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade
por: Singh, Shubhra, et al.
Publicado: (2022)

Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?
por: Cha, Edward, et al.
Publicado: (2013)

Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data
por: Reynolds, Kerry L, et al.
Publicado: (2021)

Risk of COVID‐19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors
por: Klebanov, Nikolai, et al.
Publicado: (2021)

Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors
por: Rezasoltani, Sama, et al.
Publicado: (2020)

Response to immune checkpoint blockade improved in pre-clinical model of breast cancer after bariatric surgery
por: Sipe, Laura M, et al.
Publicado: (2022)

Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2018)

Immune‐Related Adverse Events in the Setting of PD‐1/L1 Inhibitor Combination Therapy
por: Zubiri, Leyre, et al.
Publicado: (2019)

Melanoma-Specific Clinical Outcomes of Inpatient Immune Checkpoint Blockade Treatment
por: Loo, Kimberly, et al.
Publicado: (2022)

Predictors of responses to immune checkpoint blockade in advanced melanoma
por: Jacquelot, N., et al.
Publicado: (2017)

Electrocardiographic features of immune checkpoint inhibitor associated myocarditis
por: Zlotoff, Daniel A, et al.
Publicado: (2021)

Immunotherapy in Melanoma: Recent Advancements and Future Directions
por: Mooradian, Meghan J., et al.
Publicado: (2023)

Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience
por: Serpas Higbie, Victoria, et al.
Publicado: (2022)

Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction
por: Wei, Hong, et al.
Publicado: (2019)

Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC
por: Tian, Yaru, et al.
Publicado: (2020)

Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
por: Schilling, Bastian, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qtr2cosegfan5e2mvt64uedvbm